NVCR

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About NovoCure Ltd

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
CEO
Asaf Danziger
Employees
1023
Headquarters

Forum
No 4 Grenville Street, Saint Helier JE2 4UF
Phone: 441534756700
www.novocure.com

News

What''s Driving NovoCure Ltd''s Surprising 11% Stock Rally?
Jul 09, 2024 16:16pm

What''s Driving NovoCure Ltd''s Surprising 11% Stock Rally?


Source:GuruFocus
Novocure to Report Second Quarter 2024 Financial Results
Jul 01, 2024 11:00am

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three and six months ended June 30, 2024, at 8:00 a.m. EDT on Thursday, July 25, 2024. To access the conference Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
NovoCure Shareholders Elect Directors and Endorse Key Proposals
Jun 10, 2024 21:17pm

An update from NovoCure (NVCR) is now available. At NovoCure Limited’s annual general meeting on June 5, 2024, shareholders elected ten directors f…


Source:TipRanks
What''s Driving NovoCure Ltd''s Surprising 44% Stock Rally?
Jun 03, 2024 15:11pm

What''s Driving NovoCure Ltd''s Surprising 44% Stock Rally?


Source:GuruFocus
Novocure: METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
Jun 03, 2024 12:12pm

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with TTFields therapy and supportive care compared to 11.3 months for patients treated with su…


Source:Finanz Nachrichten
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
Jun 03, 2024 12:00pm

Novocure (NASDAQ: NVCR) today announced the presentation of clinical data from the phase 3 METIS trial, which investigated the use of Tumor Treating Fields (TTFields) therapy in the treatment of brain metastases from non-small cell lung cancer (NSCLC). These data will be presented at the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The METIS trial enrolled Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
May 23, 2024 21:05pm

Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the treatment of patients with newly diagnosed glioblastoma (GBM) in Germany. The TIGER study enrolled 429 patients who used TTFields therapy between August 2017 and November 2019 and is the largest prospective, Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online